Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Under-specification as the Source of Ambiguity and Vagueness in Narrative Phenotype Algorithm Definitions
Yu, Jingzhi, Ghosh, Anika, Shang, Ning , Benoit, Barbara, Carrell, David, Carroll, Robert L., Gainer, Vivian S., Håkonarson, Håkon , Mentch, Frank , Murphy, Shawn N. , Peissig, Peggy , Ramirez, Andrea, Walton, Nephi , Wei, Wei‐Qi, Carroll, Robert J. , Hakonarson, Hakon , Yu, Jingzhi, Pacheco, Jennifer A. , Luo, Yuan , Weng, Chunhua , Carroll, Robert, Dikilitas, Ozan , Freimuth, Robert R. , Hripcsak, George , Kullo, Iftikhar J. , Rasmussen, Luke V.

Mayo Clinic

No container title available | August 12, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-723873/v1 Get It

Abstract IntroductionCurrently, one of the commonly used methods for disseminating electronic health record (EHR)-based phenotype algorithms is providing a narrative description of the algorithm logic, often accompanied by flowcharts. A challenge with this mode of dissemination is the potential for under-specification in the algorithm definition, which leads to ambiguity and vagueness. MethodsThis study examines incidents of under-specification that occurred during the implementation of 34 narrative phenotyping algorithms in the electronic Medical Record and Genomics (eMERGE) network. We reviewed the online communication history between algorithm developers and implementers within the Phenotype Knowledge Base (PheKB) platform, where questions could be raised and answered regarding the intended implementation of a phenotype algorithm. ResultsWe developed a taxonomy of under-specification categories via an iterative review process between two groups of annotators. Under-specifications that lead to ambiguity and vagueness were consistently found across narrative phenotype algorithms developed by all involved eMERGE sites. Discussion & ConclusionOur findings highlight that under-specification is an impediment to the accuracy and efficiency of the implementation of current narrative phenotyping algorithms, and we propose approaches for mitigating these issues and improved methods for disseminating EHR phenotyping algorithms.
Gender Differences in Compensation in Anesthesiology in the United States: Results of a National Survey of Anesthesiologists
Hertzberg, Linda B., Miller, Thomas R. , Byerly, Stephanie I., Rebello, Elizabeth , Flood, Pamela , Malinzak, Elizabeth B. , Doyle, Christine , Pease, Sonya, Rock-Klotz, Jennifer , Kraus, Molly B. , Pai, Sher‐Lu , Pai, Sher-Lu , Kraus, Molly B , Pease, Sonya

Mayo Clinic

Anesthesia & Analgesia | August 10, 2021 | Volume: 133 | Issue: 4 | Pages: 1009-1018

10.1213/ane.0000000000005676 | PMID 34375316 Get It

BACKGROUND: A gender-based compensation gap among physicians is well documented. Even after adjusting for age, experience, work hours, productivity, and academic rank, the gender gap remained and widened over the course of a physician’s career. This study aimed to examine if a significant gender pay gap still existed for anesthesiologists in the United States. METHODS: In 2018, we surveyed 28,812 physician members of the American Society of Anesthesiologists to assess the association of compensation with gender and to identify possible causes of wage disparities. Gender was the primary variable examined in the model, and compensation by gender was the primary outcome. Compensation was defined as the amount reported as direct compensation on a W-2, 1099, or K-1, plus all voluntary salary reductions (eg, 401[k], health insurance). The survey directed respondents to include salary, bonuses, incentive payments, research stipends, honoraria, and distribution of profits to employees. Respondents had the option of providing a point estimate of their compensation or selecting a range in $50,000 increments. Potential confounding variables that could affect compensation were identified based on a scoping literature review and the consensus expertise of the authors. We fitted a generalized ordinal logistic regression with 7 ranges of compensation. For the sensitivity analyses, we used linear regressions of log-transformed compensation based on respondent point estimates and imputed values. RESULTS: The final analytic sample consisted of 2081 observations (response rate, 7.2%). This sample represented a higher percentage of women and younger physicians compared to the demographic makeup of anesthesiologists in the United States. The adjusted odds ratio associated with gender equal to woman was an estimated 0.44 (95% confidence interval, 0.37–0.53), indicating that for a given compensation range, women had a 56% lower odds than men of being in a higher compensation range. Sensitivity analyses found the relative percentage difference in compensation for women compared to men ranged from −8.3 to −8.9. In the sensitivity analysis based on the subset of respondents (n = 1036) who provided a point estimate of compensation, the relative percentage difference (−8.3%; 95% confidence interval, −4.7 to −11.7) reflected a $32,617 lower compensation for women than men, holding other covariates at their means. CONCLUSIONS: Compensation for anesthesiologists showed a significant pay gap that was associated with gender even after adjusting for potential confounding factors, including age, hours worked, geographic practice region, practice type, position, and job selection criteria.
Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)
Snyder, Rebecca A. , Le‐Rademacher, Jennifer , Dodge, Andrew , Chang, George J. , Innocenti, Federico , Blanke, Charles D. , Lenz, Heinz‐Josef, Polite, Blasé N. , Le-Rademacher, Jennifer G , Zemla, Tyler J, Polite, Blasé N , He, Jun , Ou, Fang‐Shu , Zemla, Tyler , Paskett, Electra D. , Lenz, Heinz‐Josef , Venook, Alan P. , Snyder, Rebecca A

Mayo Clinic

Cancer | August 10, 2021 | Volume: 127 | Issue: 20 | Pages: 3801-3808

10.1002/cncr.33649 | PMID 34374082 Get It

BackgroundThe objective of this study was to evaluate the association between self‐identified race and overall survival (OS), progression‐free survival (PFS), and response to therapy among patients enrolled in the randomized Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial.MethodsPatients with advanced or metastatic colorectal cancer who were enrolled in the CALGB/SWOG 80405 trial were identified by race. On the basis of covariates (treatment arm, KRAS status, sex, age, and body mass index), each Black patient was exact matched with a White patient. The association between race and OS and PFS was examined using a marginal Cox proportional hazard model for matched pairs. The interaction between KRAS status and race was tested in the model. The association between race and response to therapy and adverse events were examined using a marginal logistic regression model.ResultsIn total, 392 patients were matched and included in the final data set. No difference in OS (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.73‐1.16), PFS (HR, 0.97; 95% CI, 0.78‐1.20), or response to therapy (odds ratio [OR], 1.00; 95% CI, 0.65‐1.52) was observed between Black and White patients. Patients with KRAS mutant status (HR, 1.31; 95% CI, 1.02‐1.67), a performance statusscore of 1 (reference, a performance status of 0; HR, 1.49; 95% CI, 1.18‐1.88), or ≥3 metastatic sites (reference, 1 metastatic site; HR, 1.67; 95% CI, 1.22‐2.28) experienced worse OS. Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24‐0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72‐1.65).ConclusionsNo difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial.Lay Summary Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer. The purpose of this study was to determine whether there was a difference in cancer‐specific outcomes among Black and White patients receiving equivalent treatment on the CALGB/SWOG 80405 randomized clinical trial. In this study, there was no difference in overall survival, progression‐free survival, or response to therapy between Black and White patients treated on a clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.
Rapid Independent Health Literacy Assessment: A Pilot Study Among Native English-speaking and Low English Proficiency Patients
Hargiss, J. Blade , Jeor, Jeffery D. St. , Horn, Jennifer L. , Garrison, Gregory M. , Hargiss, John Blade

Mayo Clinic

Journal of Primary Care & Community Health | August 6, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211037773 | PMID 34355598 Get It

Objectives: Health literacy is an individual’s capacity to obtain, process, and understand basic health information needed to make appropriate health decisions. Failure to understand and correctly execute a plan of care often leads to poor health outcomes. Determining patient health literacy allows health care providers to tailor their plan of care instructions, increasing the probability of understanding, and adherence. Several validated health literacy tests have been developed to assess the health literacy of individuals and ethnic groups. However, because a proctor is required to administer these tests, their usefulness in clinical settings is limited. The issue of health literacy is especially relevant within minority groups. This research focused on producing a translatable assessment that can be administered quickly without a proctor. Methods: We developed a 15-question instrument (the RIHLA) in English using the Delphi method with a panel of bilingual experts and translated it into Spanish. Internal reliability was assessed using Cronbach’s alpha for 3 groups: Native English-speaking College students (NESC), Native English-speaking patients (NES), and Limited English Proficient Spanish-speaking patients (LEP). External validity was assessed using Pearson’s correlation coefficient to compare our instrument to a previously validated, proctored instrument measuring health literacy (the SAHL-E). Results: Four hundred fifteen subjects completed the RIHLA. Of these, 192 (46.3%) were NESC, 208 (50.1%) were NES, and 15 (3.6%) were LEP. The mean number of correct answers was 11.2, 11.6, and 8.3 respectively with the LEP group scoring lower ( P < .01). Cronbach’s alpha was >.70 for each group. Moderate correlation between the RIHLA and the previously validated instrument was present ( P < .01) with Pearson’s r = .47 (95% CI: 0.18-0.69). Conclusion: The RIHLA is a non-proctored assessment tool that may provide a measure of patients’ health literacy in multiple languages. Further studies with larger sample sizes are necessary to confirm the reliability, validity, and generalizability to a wider population.
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases
Begna, Kebede H. , Kittur, Jaya, Yui, Jennifer , Gangat, Naseema , Patnaik, Mrinal M. , Al‐Kali, Aref , Elliott, Michelle A. , Litzow, Mark R. , Hook, C. Christopher , Wolanskyj, Alexandra P. , Howard, Matthew T., Hanson, Curtis A. , Pardanani, Animesh , Tefferi, Ayalew , Hook, Christopher C., Pardanani, Animesh , Tefferi, Ayalew , Wolanskyj-Spinner, Alexandra P , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

British Journal of Haematology | August 4, 2021 | Volume: 195 | Issue: 3 | Pages: 413-416

10.1111/bjh.17742 | PMID 34346084 Get It

SummaryInstitutional database search (1999–2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment‐induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.
Prevention of Allergic-like Reactions at Repeat CT: Steroid Pretreatment versus Contrast Material Substitution
McDonald, Jennifer S. , Larson, Nicholas B. , Kolbe, Amy B. , Schmitz, John J. , Maddox, Daniel E. , Hartman, Robert P. , Kallmes, David F. , McDonald, Robert J. , Hunt, Christopher H , Schmitz, John J , Maddox, Daniel E , Hartman, Robert P , Kallmes, David F , McDonald, Robert J , Larson, Nicholas B , Hunt, Christopher H.

Mayo Clinic

Radiology | August 3, 2021 | Volume: 301 | Issue: 1 | Pages: 133-140

10.1148/radiol.2021210490 | PMID 34342504 Get It

Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review
Chan, David , Bergsland, Emily K. , Chan, Jennifer A. , Gadgil, Rujuta, Hornbacker, Kathleen , Kelly, Virginia, Kunz, Pamela L. , McGarrah, Patrick W. , Raj, Nitya , Reidy‐Lagunes, Diane , Thawer, Alia , Whitman, Julia, Wu, Linda Y. , Becker, Christoph R. , Singh, Simron , Chan, David L , McGarrah, Patrick , Hálfdánarson, Þorvarður R.

Mayo Clinic

The Oncologist | August 3, 2021 | Volume: 26 | Issue: 11 | Pages: 950-955

10.1002/onco.13923 | PMID 34342086 Get It

Abstract Background Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of neuroendocrine neoplasms (NENs). Temozolomide (TEM)-based regimens have been increasingly used to treat grade 1–2 NENs, but their efficacy in G3 NENs remains undetermined. We aimed to assess the clinical efficacy of TEM-containing regimens in advanced grade 3 GEPNENs. Materials and Methods A multicenter retrospective review (2008–2018) of patients with metastatic/unresectable G3 GEPNENs who received a TEM-containing regimen was undertaken within a North American partnership to pool data. The primary endpoint was time to treatment failure (TTF). Radiologic response was extracted from local reports. Results One hundred and thirty patients in six high-volume NEN centers were included (median age 55, 64% male, 18% functional, 67% pancreatic NEN). Forty-nine percent were well-differentiated, 35% poorly differentiated, and 15% unknown based on local pathology reports. The regimen used was capecitabine and temozolomide (CAPTEM) in 92% and TEM alone in 8%. Radiological response by local assessment was seen in 36% of patients. Median TTF was 3.6 months and median overall survival (OS) 19.2 months. Six percent of patients required discontinuation of therapy due to adverse events. TTF was longer in first-line treatment (7.8 months vs. 2.9 months; hazard ratio, 1.62; 95% confidence interval, 1.11–2.36; p = .015) and in patients with pancreatic NENs (panNENs) compared with gastrointestinal NENs (5.8 months vs 1.8 months; p = .04). The overall response rate was higher in the first-line setting (51% vs 29%; p = .02) and in panNEN (41% vs 23%; p = .04). Conclusion This is the largest TEM treatment series in G3 NEN, involving collaboration of several major North American NEN centers as a partnership. Thirty-six percent of patients showed some degree of radiographic response, and treatment was generally well tolerated, although the median duration of response was short. Response rates and time to treatment failure were superior in the first-line setting. CAPTEM should be considered a viable treatment option in this setting. Further randomized trials are warranted. Implications for Practice Neuroendocrine neoplasms (NENs) are heterogeneous, and optimal treatment for aggressive grade 3 (G3) NENs remains undetermined. The capecitabine and temozolomide (CAPTEM) regimen has been used in low-grade pancreas NENs but there are few data for its safety and efficacy in the G3 setting. This article reports on the efficacy of temozolomide-containing regimens, particularly CAPTEM, in management of G3 NENs. The good tolerance and response rate show that CAPTEM should be considered a viable regimen in treatment of G3 NENs pending confirmatory prospective studies.
NCCN Guidelines® Insights: Palliative Care, Version 2.2021
Dans, Maria, Kutner, Jean S. , Agarwal, Rajiv , Baker, Justin N. , Bauman, Jessica R. , Carey, Elise C. , Dalal, Shalini , Doberman, Danielle J. , Fecher, Leslie A. , Kapo, Jennifer, Lee, Richard T. , McCammon, Susan , Mitchell, William M. , Ogunseitan, Adeboye, Portman, Diane , Ramchandran, Kavitha , Sutton, Linda , Teply, Melissa , Terauchi, Stephanie , Walling, Anne M. , Zachariah, Finly , Bergman, Mary Anne, Ogba, Ndiya , Campbell, Mallory, Agarwal, Rajiv , Ramchandran, Kavitha J , Beck, Anna Catherine , Campbell, Toby C. , Case, Amy Allen , Epstein, Andrew S , Jones, Joshua , Loggers, Elizabeth T , Mitchell, William, Temel, Jennifer S. , Thomas, Jane deLima

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 780-788

10.6004/jnccn.2021.0033 | PMID 34340208 Get It

Palliative care has evolved to be an integral part of comprehensive cancer care with the goal of early intervention to improve quality of life and patient outcomes. The NCCN Guidelines for Palliative Care provide recommendations to help the primary oncology team promote the best quality of life possible throughout the illness trajectory for each patient with cancer. The NCCN Palliative Care Panel meets annually to evaluate and update recommendations based on panel members’ clinical expertise and emerging scientific data. These NCCN Guidelines Insights summarize the panel’s recent discussions and highlights updates on the importance of fostering adaptive coping strategies for patients and families, and on the role of pharmacologic and nonpharmacologic interventions to optimize symptom management.
Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers
Breuer, Eva , Mizuno, Takashi , Bartsch, F. , Ratti, Francesca , Benzing, Christian , Ammar-Khodja, Noémie, Sugiura, Teiichi , Takayashiki, Tsukasa , Hessheimer, Amelia J. , Kim, Hyung Sun , Ahn, Keun Soo , Wong, Tiffany , D’Silva, Mizelle , Koerkamp, Bas Groot , Jeddou, Heithem , Ponthaud, Charles de , Ismail, Warsan, Nooijen, Lynn E. , Hidalgo-Salinas, Camila, Wagner, Kim C. , Gunasekaran, Ganesh , Higuchi, Ryota , Gleisner, Ana , Shwaartz, Chaya , Schulick, Richard D. , Yamamoto, Masakazu , Schwartz, Myron , Oldhafer, Karl J. , Prachalias, Andreas , Fusai, Giuseppe , Erdmann, Joris I. , Line, Pål‐Dag , Smoot, Rory L. , Robles, R , Boudjéma, Karim , Polak, Wojciech G. , Neumann, Ulf P. , Lo, Chung‐Mau, Kang, Koo Jeong , Park, Joon Seong , Fondevila, Constantino , Uesaka, Katsuhiko , Pratschke, Johann , Aldrighetti, Luca , Oliveira, Michelle, Lang, Hauke , Nagino, Masato , Clavien, Pierre‐Alain , Yonkus, Jennifer A. , Line, Pål Dag , Smoot, Rory L , Aldrighetti, Luca , Erdmann, Joris I , Polak, Wojciech G , Wong, Tiffany C L , De Ponthaud, Charles , Groot Koerkamp, Bas , Ratti, Francesca , Mueller, Matteo , Kim, Hyung Sun, Ruzzenente, Andrea , Ahn, Keun Soo, Wong, Tiffany, Bednarsch, Jan , Jeddou, Heithem, Lopez-Lopez, Víctor; https://orcid.org/0000-0003-1718-3352, Kontis, Elissaios A. , Higuchi, Ryota, al, et, Schulick, Richard D., Yamamoto, Masakazu, Noji, Takehiro , Hirano, Satoshi, Schwartz, Myron, Oldhafer, Karl J., Fusai, Giuseppe K., Soubrane, Olivier , Polak, Wojciech G.; id_orcid 0000-0002-3096-4893, Han, Ho Seong, Neumann, Ulf P., Lo, Chung Mau , Guglielmi, Alfredo , Ohtsuka, Masayuki , Adam, René, Pratschke, Johann, Oliveira, Michelle L. De, Gores, Gregory J.

Mayo Clinic

Annals of Surgery | August 2, 2021 | Volume: 274 | Issue: 5 | Pages: 780-788

10.1097/sla.0000000000005103 | PMID 34334638 Get It

Objective: The aim of this study was to define robust benchmark values for the surgical treatment of perihilar cholangiocarcinomas (PHC) to enable unbiased comparisons. Background: Despite ongoing efforts, postoperative mortality and morbidity remains high after complex liver surgery for PHC. Benchmark data of best achievable results in surgical PHC treatment are however still lacking. Methods: This study analyzed consecutive patients undergoing major liver surgery for PHC in 24 high-volume centers in 3 continents over the recent 5-year period (2014–2018) with a minimum follow-up of 1 year in each patient. Benchmark patients were those operated at high-volume centers (≥50 cases during the study period) without the need for vascular reconstruction due to tumor invasion, or the presence of significant co-morbidities such as severe obesity (body mass index ≥35), diabetes, or cardiovascular diseases. Benchmark cutoff values were derived from the 75th or 25th percentile of the median values of all benchmark centers. Results: Seven hundred eight (39%) of a total of 1829 consecutive patients qualified as benchmark cases. Benchmark cut-offs included: R0 resection ≥57%, postoperative liver failure (International Study Group of Liver Surgery): ≤35%; in-hospital and 3-month mortality rates ≤8% and ≤13%, respectively; 3-month grade 3 complications and the CCI: ≤70% and ≤30.5, respectively; bile leak-rate: ≤47% and 5-year overall survival of ≥39.7%. Centers operating mostly on complex cases disclosed better outcome including lower post-operative liver failure rates (4% vs 13%; P = 0.002). Centers from Asia disclosed better outcomes. Conclusion: Surgery for PHC remains associated with high morbidity and mortality with now the availability of benchmark values covering 21 outcome parameters, which may serve as key references for comparison in any future analyses of individuals, group of patients or centers.